Merck's renal cell carcinoma drug highlights systemic gaps in cancer innovation and equity
Original framing: “STAT+: A Merck cancer drug to watch” — STAT News
The article references the Henrietta Lacks case, which is a significant historical injustice in medical research. However, it lacks deeper historical analysis of how systemic inequities in healthcare have evolved over time and how they continue to shape current practices.
The article reveals how Merck’s renal cell carcinoma drug, while a scientific advancement, is embedded in a system that perpetuates historical and ongoing inequities in healthcare.
By highlighting the Henrietta Lacks settlement, it points to the need for deeper structural reform in consent, data governance, and access. Integrating Indigenous and cross-cultural knowledge, centering marginalized voices, and reimagining innovation through ethical and equitable frameworks are essential to transforming the current paradigm. A trickster lens would question the uncritical celebration of pharmaceutical progress and expose the hidden costs of such innovation. Without systemic change, the promise of new drugs will continue to be undermined by the same patterns of exclusion and exploitation.